摘要
目的:评估补肾清透方对HBe Ag阳性HBV携带者细胞因子的影响、抗病毒疗效及安全性。方法:选取60例符合肾虚证的HBe Ag阳性慢性乙肝病毒携带者,随机分为治疗组(40例)和对照组(20例),治疗组予以中药补肾清透干预,对照组予以安慰剂干预,疗程均为48周。治疗前及治疗后第48周检测所有入组患者外周血的IL-2、IL-10、TNF-α、IFN-γ、HBe Ag、HBe Ab及HBV-DNA。结果:治疗48周后,治疗组升高血清IL-2、TNF-α、IFN-γ水平的程度高于对照组,两组比较均有统计学差异(P<0.01);治疗组降低IL-10水平的程度也高于对照组,两组比较有统计学差异(P<0.01);治疗组HBe Ag阴转率及HBe Ag/HBe Ab血清转换率均高于对照组,两组比较均有统计学差异(P<0.01);治疗组血清HBV-DNA下降>1 log10、>2 logl0、>3 log10及HBVDNA阴转的例数明显多于对照组,两组比较均有统计学差异(P<0.01)。结论:补肾清透方可改善ASC患者的免疫功能,且有一定抑制HBV的作用,可能与改善T细胞功能有关,安全性良好。
Objective: To evaluate the effects of cytokines,antiviral therapeutic effects and safety of Bushen Qingtou prescription on hepatitis B virus( HBV) carriers with positive HBe Ag. Methods: 60 cases of kidney deficiency syndrome with positive HBe Ag HBV carriers were randomly divided into treatment group( 40 cases) and control group( 20 cases).The Chinese medicine Bushen Qingtou prescription was applied in treatment group and placebo was applied in control group for a course of 48 weeks. Before and 48 weeks after treatment,the detections of IL- 2,IL- 10,TNF- α,IFN- γ,HBe Ag,HBe Ab and HBV- DNA of peripheral blood were carried out. Result: After 48 weeks,the extent of the treatment group increased IL- 2,TNF- α and IFN- γ,higher than those of control group and the two groups had statistical difference( P〈 0. 01). The reduced extent of the treatment group's IL- 10 was higher than that of control group and the two groups had statistical difference( P〈 0. 01). The negative rate of HBV- DNA and HBe Ag / HBe Ab serum conversion rate in treatment group was higher than that of control group and the two groups had statistical difference( P〈 0. 01). The cases of the treatment group which had decreased HBV DNA 1 log10, 2 logl0, 3 log10 and negative conversion of HBV- DNA were significantly more than those of the control group and the two groups had statistical difference( P〈 0. 01). Conclusion: Bushen Qingtou prescription can improve immune function of ASC and has the function of HBV inhibition,which may be related to improving the function of T cells with good security.
出处
《中华中医药学刊》
CAS
北大核心
2015年第3期543-545,共3页
Chinese Archives of Traditional Chinese Medicine
基金
国家"十一五"科技重大专项项目(2008ZX10005-008)